Tuberculosis (TB) is the most serious and most common opportunistic infection, and the most common cause of death in human immunodeficiency virus (HIV) patients. Globally, a significant challenge to achieving universal access to HIV prevention, treatment, care and support is the optimization of imaging. In this regard, nuclear medicine with both positron emission tomography (PET) and single-photon emission computed tomography (SPECT) is an integral part of infection imaging. HIV primarily infects and kills helper T cells (CD4+ T cells), macrophages and dendritic cells. In HIV/acquired immunodeficiency syndrome (AIDS) and TB infection, early identification and diagnosis of active TB is the key to effective control of the disease. Patients with HIV-1 are at risk for lymphoma, making the differential diagnosis between benign and malignant lymphadenopathy imperative. In developing countries, multidrug resistant (MDR) and extensively drug resistant (XDR) TB are of serious consequence and thus monitoring of therapy is essential.
Nuclear Medicine Imaging of Tuberculosis and Human Immunodefi ciency Virus / Sathekge, M.; Van de Wiele, C.; Signore, A.. - (2013), pp. 255-272. [10.1002/9781118484388.ch15].
Nuclear Medicine Imaging of Tuberculosis and Human Immunodefi ciency Virus
Signore A.
2013
Abstract
Tuberculosis (TB) is the most serious and most common opportunistic infection, and the most common cause of death in human immunodeficiency virus (HIV) patients. Globally, a significant challenge to achieving universal access to HIV prevention, treatment, care and support is the optimization of imaging. In this regard, nuclear medicine with both positron emission tomography (PET) and single-photon emission computed tomography (SPECT) is an integral part of infection imaging. HIV primarily infects and kills helper T cells (CD4+ T cells), macrophages and dendritic cells. In HIV/acquired immunodeficiency syndrome (AIDS) and TB infection, early identification and diagnosis of active TB is the key to effective control of the disease. Patients with HIV-1 are at risk for lymphoma, making the differential diagnosis between benign and malignant lymphadenopathy imperative. In developing countries, multidrug resistant (MDR) and extensively drug resistant (XDR) TB are of serious consequence and thus monitoring of therapy is essential.File | Dimensione | Formato | |
---|---|---|---|
Sathekge_Nuclear_2013.pdf
solo gestori archivio
Note: Chapter 15
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
736.64 kB
Formato
Adobe PDF
|
736.64 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.